FLIXOTIDE NEBULES 0.5 mg2 ml

Valsts: Singapūra

Valoda: angļu

Klimata pārmaiņas: HSA (Health Sciences Authority)

Aktīvā sastāvdaļa:

FLUTICASONE PROPIONATE (micronised)

Pieejams no:

GLAXOSMITHKLINE PTE LTD

ATĶ kods:

R03BA05

Deva:

0.5 mg/2 ml

Zāļu forma:

SOLUTION

Kompozīcija:

FLUTICASONE PROPIONATE (micronised) 0.5 mg/2 ml

Ievadīšanas:

RESPIRATORY (INHALATION)

Receptes veids:

Prescription Only

Ražojis:

GLAXOSMITHKLINE AUSTRALIA PTY LTD

Autorizācija statuss:

ACTIVE

Autorizācija datums:

1999-09-14

Lietošanas instrukcija

 
1 of 10 
FLIXOTIDE™ NEBULES™ 
FLUTICASONE PROPIONATE 

QUALITATIVE AND QUANTITATIVE COMPOSITION 
Fluticasone propionate 0.5 mg in 2 ml._ _
_FLIXOTIDE_ _NEBULES_ (plastic ampoules) are intended
for nebulisation and contain 0.5 
mg of fluticasone propionate (micronised) as a 2 ml buffered
isotonic saline suspension. 
PHARMACEUTICAL FORM 
Suspension for inhalation by nebulisation. 
CLINICAL PARTICULARS 
INDICATIONS 
ASTHMA 
_FLIXOTIDE_ has a marked anti-inflammatory effect in the lungs. 
It reduces symptoms and
exacerbations of asthma in patients previously treated with 
bronchodilators alone or with other prophylactic therapy. 
Relatively brief symptomatic episodes can generally be relieved
by the use of fast-acting 
bronchodilators, but longer lasting exacerbations require, in
addition, the use of 
corticosteroid therapy as soon as possible, to
control the inflammation. 
•  ADULTS AND ADOLESCENTS OVER 16 YEARS OF AGE 
Prophylactic management in
severe asthma (Patients requiring high dose inhaled or oral 
corticosteroid therapy): 
On introduction of inhaled _FLIXOTIDE _many patients who
are dependent on systemic 
corticosteroids for adequate control of symptoms may be able to
reduce significantly or to 
eliminate their requirement for oral corticosteroids. 
•  CHILDREN AND ADOLESCENTS FROM 4 TO 16 YEARS OF AGE 
Treatment of acute exacerbations of asthma: 

2 of 10 
Subsequent maintenance dosing may be more conveniently accomplished
using a 
pressurised metered-dose inhaler or powder formulation. 
DOSAGE AND ADMINISTRATION 
Patients should
be made aware of the prophylactic nature of therapy with
inhaled 
_FLIXOTIDE_ and that it should be taken regularly even when
they are asymptomatic._ _
_FLIXOTIDE _Nebules should be administered as an aerosol produced
by a jet nebuliser, as 
directed by a physician.  As drug�

Produkta apraksts

1 of 11
FLIXOTIDE NEBULES
FLUTICASONE PROPIONATE
QUALITATIVE AND QUANTITATIVE COMPOSITION
Fluticasone propionate 0.5 mg in 2 ml.
_ _
_FLIXOTIDE_
_NEBULES_
(plastic ampoules) are intended for nebulisation and contain 0.5
mg of fluticasone propionate (micronised) as a 2 ml buffered isotonic
saline suspension.
CLINICAL INFORMATION
INDICATIONS
ASTHMA
_FLIXOTIDE_
has a marked anti-inflammatory effect in the lungs.
It reduces symptoms and exacerbations of asthma in patients previously
treated with
bronchodilators alone or with other prophylactic therapy.
Relatively brief symptomatic episodes can generally be relieved by the
use of fast-acting
bronchodilators, but longer lasting exacerbations require, in
addition, the use of
corticosteroid therapy as soon as possible, to control the
inflammation.
•
ADULTS AND ADOLESCENTS OVER 16 YEARS OF AGE
Prophylactic management in severe asthma (Patients requiring high dose
inhaled or oral
corticosteroid therapy):
On introduction of inhaled
_FLIXOTIDE _
many patients who are dependent on systemic
corticosteroids for adequate control of symptoms may be able to reduce
significantly or
to eliminate their requirement for oral corticosteroids.
•
CHILDREN AND ADOLESCENTS FROM 4 TO 16 YEARS OF AGE
Treatment of acute exacerbations of asthma:
Subsequent maintenance dosing may be more conveniently accomplished
using a
pressurised metered-dose inhaler or powder formulation.
DOSAGE AND ADMINISTRATION
Pharmaceutical form: Suspension for inhalation by nebulisation.
Patients should be made aware of the prophylactic nature of therapy
with inhaled
_FLIXOTIDE_
and that it should be taken regularly even when they are asymptomatic.
_ _
2 of 11
_FLIXOTIDE _
Nebules should be administered as an aerosol produced by a jet
nebuliser, as
directed by a physician. As drug delivery can be affected by a wide
range of criteria,
please refer to the directions recommended by the manufacturer of the
nebuliser
equipment.
Use of
_FLIXOTIDE _
Nebules with ultrasonic nebulisers is not generally recommended.
_FLIXOTI